Literature DB >> 12453969

Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity.

José Manuel Fernández-Real1, Georgina Peñarroja, Antoni Castro, Fernando García-Bragado, Abel López-Bermejo, Wifredo Ricart.   

Abstract

OBJECTIVE: In a recent study, iron chelation with deferoxamine led to improvement of endothelial dysfunction in patients with coronary artery disease. We tested the hypothesis that decreasing circulating iron stores might improve vascular dysfunction in patients with type 2 diabetes and increased serum ferritin concentration. RESEARCH DESIGN AND METHODS: A total of 28 type 2 diabetic male patients with serum ferritin levels >200 ng/ml ( approximately 18% of consecutive type 2 diabetic men attending our outpatient clinic) were randomized to iron depletion (three extractions of 500 ml blood at 2-week intervals; group 1A) or to observation (group 1B). C282Y mutation was absent in all patients. Vascular reactivity (high-resolution external ultrasound) was evaluated at baseline and at 4 and 12 months thereafter. The two groups of patients were matched for age, BMI, pharmacological treatment, and chronic diabetic complications.
RESULTS: Endothelium-dependent vasodilation remained essentially unchanged in both groups of patients. In contrast, the vasodilation induced by glyceryl trinitrate (GTN) improved significantly after iron depletion (P = 0.006). These changes occurred in parallel to decreases in transferrin saturation index and HbA(1c) levels (-0.6%, P < 0.05) only in group 1A patients. The best predictor of the modifications in endothelium-independent vasodilation was the change in HbA(1c) levels. Changes in endothelium-independent vasodilation also correlated with the change in serum ferritin (r = -0.45, P = 0.04). At 12 months, transferrin saturation index and GTN-induced vasodilation returned to values similar to those at baseline in both groups of subjects.
CONCLUSIONS: Iron depletion improves vascular dysfunction in type 2 diabetic patients with high ferritin concentrations. The mechanisms by which these changes occur should be further investigated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12453969     DOI: 10.2337/diacare.25.12.2249

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  16 in total

1.  Non-alcoholic fatty liver disease: is iron relevant?

Authors:  Julia O'Brien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2011-08-12       Impact factor: 6.047

2.  Dietary iron restriction or iron chelation protects from diabetes and loss of beta-cell function in the obese (ob/ob lep-/-) mouse.

Authors:  Robert C Cooksey; Deborah Jones; Scott Gabrielsen; Jingyu Huang; Judith A Simcox; Bai Luo; Yudi Soesanto; Hugh Rienhoff; E Dale Abel; Donald A McClain
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-03-30       Impact factor: 4.310

Review 3.  Iron and diabetes risk.

Authors:  Judith A Simcox; Donald A McClain
Journal:  Cell Metab       Date:  2013-03-05       Impact factor: 27.287

4.  Chelation of dietary iron prevents iron accumulation and macrophage infiltration in the type I diabetic kidney.

Authors:  Tatsuyori Morita; Daisuke Nakano; Kento Kitada; Satoshi Morimoto; Atsuhiro Ichihara; Hirofumi Hitomi; Hiroyuki Kobori; Ichiro Shiojima; Akira Nishiyama
Journal:  Eur J Pharmacol       Date:  2015-03-26       Impact factor: 4.432

5.  Adipocyte iron regulates adiponectin and insulin sensitivity.

Authors:  J Scott Gabrielsen; Yan Gao; Judith A Simcox; Jingyu Huang; David Thorup; Deborah Jones; Robert C Cooksey; David Gabrielsen; Ted D Adams; Steven C Hunt; Paul N Hopkins; William T Cefalu; Donald A McClain
Journal:  J Clin Invest       Date:  2012-09-10       Impact factor: 14.808

6.  Reduced iron stores and its effect on vasovagal syncope (simple faint).

Authors:  Julian M Stewart
Journal:  J Pediatr       Date:  2008-07       Impact factor: 4.406

Review 7.  Iron in chronic brain disorders: imaging and neurotherapeutic implications.

Authors:  James Stankiewicz; S Scott Panter; Mohit Neema; Ashish Arora; Courtney E Batt; Rohit Bakshi
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

8.  Biomarkers of body iron stores and risk of developing type 2 diabetes.

Authors:  S N Rajpathak; J Wylie-Rosett; M J Gunter; A Negassa; G C Kabat; T E Rohan; J Crandall
Journal:  Diabetes Obes Metab       Date:  2009-01-21       Impact factor: 6.577

Review 9.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

10.  Hyperferritinemia and hyperuricemia may be associated with liver function abnormality in obese adolescents.

Authors:  Solomon Chih Cheng Chen; Ya Fang Huang; Jung Der Wang
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.